-
Mashup Score: 6What is the rationale for monitoring secondary malignancies after BCMA and CD19 CAR T-cell therapy? - 2 day(s) ago
The Multiple Myeloma Hub and Lymphoma Hub were pleased to speak to Anna Sureda, Catalan Institute of Oncology, Barcelona, ES. We asked, What is the rationale for monitoring secondary malignancies after BCMA and CD19 CAR T-cell therapy?
Source: multiplemyelomahub.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 23Symposium | BCMA-directed bispecific antibodies - 3 day(s) ago
During the Multiple Myeloma Hub virtual symposium, Naresh Bumma, The Ohio State University, Columbus, US, delivered a presentation on BCMA-directed bispecific antibodies in MM.
Source: multiplemyelomahub.comCategories: General Medicine News, Onc News and JournalsTweet-
In our recent symposium, Naresh Bumma delved into BCMA-directed #bispecific antibodies for MM. βWe need to consider patient-specific clinical factors. Access is very important, and obviously patient preference is very important.β Catch up below π https://t.co/TunXO7MHUG https://t.co/kEoaJwZphF
-
-
Mashup Score: 20
Here, we summarize a publication by Mohty et al. in the British Journal of Haematology on patient-reported outcomes following treatment with elranatamab in the phase II MagnetisMM-3 clinical trial.
Source: multiplemyelomahub.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 5
Here, we summarize a subanalysis by Oriol et al. published in Clinical Lymphoma, Myeloma and Leukemia on the results of the OPTIMISMM trial by frailty status and bortezomib dose adjustment.
Source: multiplemyelomahub.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 40
The Multiple Myeloma Hub virtual symposium was chaired by Sagar Lonial, and featured expert presentations from Naresh Bumma, Amrita Krishnan, and Sergio Giralt.
Source: multiplemyelomahub.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 13Infections following bispecific antibody therapy in MM: incidence and characteristics - 12 day(s) ago
Here, we summarize a multicenter, retrospective study conducted in France on the incidence and characteristics of infections following treatment with bispecific antibody therapy.
Source: multiplemyelomahub.comCategories: General Medicine News, Onc News and JournalsTweet-
Did you know that 44% of infections after treatment with #bispecific antibodies are in the lower respiratory tract? Our latest article details the incidence and characteristics of infections associated with the use of bsAbs! π https://t.co/Wa3rGGAVFq #mmsm #MultipleMyeloma https://t.co/xhLYUMCXMb
-
-
Mashup Score: 4
Here, we summarize a publication by Murugappan, et al. in Journal of Geriatric Oncology on a comparison between approaches to measuring frailty: the patient-reported frailty phenotype (PRFP) and the International Myeloma Working Group Frailty Index (IMWG FI).
Source: multiplemyelomahub.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 41
The Multiple Myeloma Hub virtual symposium was chaired by Sagar Lonial, and featured expert presentations from Naresh Bumma, Amrita Krishnan, and Sergio Giralt.
Source: multiplemyelomahub.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 5
On April 5, 2024, the U.S. FDA granted approval to idecabtagene vicleucel for the treatment of triple-class-exposed relapsed/refractory multiple myeloma after two or more prior therapies, including an immunomodulatory agent, proteasome inhibitor, and an anti-CD38 antibody.
Source: multiplemyelomahub.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 2CAR T-cell therapy in older patients: Efficacy and rates of immune-mediated toxicity - 22 day(s) ago
We summarize a systematic review and meta-analysis by Akhtar et al. investigating the efficacy of CAR T-cell therapy and rates of immune-mediated toxicity in patients β₯65 years old with multiple myeloma.
Source: multiplemyelomahub.comCategories: General Medicine News, Onc News and JournalsTweet
π₯ The Multiple Myeloma Hub and @LymphomaHub were pleased to speak to @AnnaSureda5. We asked, What is the rationale for monitoring secondary malignancies after BCMA and CD19 CAR T-cell therapy? Watch here: https://t.co/lWNPhg6H5p #mmsm #myeloma https://t.co/MUNntngR7p